Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash from Operations (2016 - 2026)

Heron Therapeutics filings provide 15 years of Cash from Operations readings, the most recent being 1540000.0 for Q1 2026.

  • On a quarterly basis, Cash from Operations rose 82.64% to 1540000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 20261000.0, a 7.41% increase, with the full-year FY2025 number at 27591000.0, down 22.47% from a year prior.
  • Cash from Operations hit 1540000.0 in Q1 2026 for Heron Therapeutics, up from 9184000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 3371000.0 in Q3 2024 to a low of 43939000.0 in Q1 2022.
  • Median Cash from Operations over the past 5 years was 9516000.0 (2024), compared with a mean of 15138882.35.
  • The widest YoY moves for Cash from Operations: up 136.73% in 2024, down 579.84% in 2024.
  • Heron Therapeutics' Cash from Operations stood at 37534000.0 in 2022, then surged by 106.54% to 2455000.0 in 2023, then plummeted by 579.84% to 11780000.0 in 2024, then rose by 22.04% to 9184000.0 in 2025, then soared by 83.23% to 1540000.0 in 2026.
  • The last three reported values for Cash from Operations were 1540000.0 (Q1 2026), 9184000.0 (Q4 2025), and 1331000.0 (Q3 2025) per Business Quant data.